These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11069790)

  • 1. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
    Jasmer RM; Snyder DC; Chin DP; Hopewell PC; Cuthbert SS; Antonio Paz E; Daley CL
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1648-52. PubMed ID: 11069790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
    Goldberg SV; Duchin JS; Shields T; Nolan CM
    Am J Respir Crit Care Med; 1999 Aug; 160(2):508-12. PubMed ID: 10430721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    Am J Respir Crit Care Med; 2009 Jun; 179(11):1055-60. PubMed ID: 19299495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K; Aspler A; Menzies D; Schwartzman K
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
    Menzies D; Dion MJ; Rabinovitch B; Mannix S; Brassard P; Schwartzman K
    Am J Respir Crit Care Med; 2004 Aug; 170(4):445-9. PubMed ID: 15172892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN
    Ann Intern Med; 1998 Nov; 129(10):779-86. PubMed ID: 9841583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
    Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D
    Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD; Mylonakis E
    Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].
    Martínez Alfaro E; Solera J; Serna E; Cuenca D; Castillejos ML; Espinosa A; Sáez L
    Med Clin (Barc); 1998 Oct; 111(11):401-4. PubMed ID: 9834911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines.
    McNab BD; Marciniuk DD; Alvi RA; Tan L; Hoeppner VH
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):989-93. PubMed ID: 10988118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
    Al-Dossary FS; Ong LT; Correa AG; Starke JR
    Pediatr Infect Dis J; 2002 Feb; 21(2):91-7. PubMed ID: 11840073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.